Abstract:Abstract Abstract #1111 Rats treated with the carcinogen methylnitrosourea (MNU) develop multiple, hormonally dependent mammary tumors. The efficacy of the epidermal growth factor receptor (EGFR) inhibitor Gefitinib (Iressa) to prevent MNU-induced mammary cancers in female Sprague-Dawley rats was determined. Rats were given a single dose of MNU (75 mg/kg body weight) at 50 days of age. Rats bearing MNU-induced small palpable cancers showed variable responses to treatment with Iressa; with approximately 50% having a complete regression and the remaining 50% having a partial or no response. We conducted exon array studies of differentially expressed genes and/or alternative splicing exons related to the responses (complete vs partial or no response). Preliminary studies showed that, although there were genes whose expression was similarly modulated in both groups, a gene expression signature can be identified that is highly predictive of which rat mammary tumors are susceptible to treatment with Iressa. Cross validation results indicated that gene expression signatures may be useful in predicting the response of a rat mammary tumor to treatment with Iressa. Currently, we are conducting validation studies in a separate set of rat mammary tumors. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1111.

Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 2 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Figure 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER+ Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Figure Legend from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Tables 1-7 from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

A Gene Expression Signature Predicts Chemopreventive Response of an EGFR Inhibitor in a Rat Mammary Cancer Model.

Supplementary Table 3 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Table 1 from Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma

Supplementary Table 1, Figure Legends 1-2 from Genetic Variants in Oxidative Stress–Related Genes Predict Chemoresistance in Primary Breast Cancer: A Prospective Observational Study and Validation

Supplementary Table 3 from AC1MMYR2, an Inhibitor of Dicer-Mediated Biogenesis of Oncomir Mir-21, Reverses Epithelial–Mesenchymal Transition and Suppresses Tumor Growth and Progression

Supplementary Table 1 from NCOA1 Directly Targets <i>M-CSF1</i> Expression to Promote Breast Cancer Metastasis

Supplementary Tables (S1-S2) from Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer Via Activation of Mir-126-5p/β-catenin/cbp Signaling

Supplementary Table 1 from AC1MMYR2, an Inhibitor of Dicer-Mediated Biogenesis of Oncomir miR-21, Reverses Epithelial–Mesenchymal Transition and Suppresses Tumor Growth and Progression

Supplementary Figure 2 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or Without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Supplementary Figure 1 from Dual Inhibition of PI3K and Mtor Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Supplementary Table S2 from <i>birc6</i> Targeting As Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 1 from Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

Supplementary Methods and Table from Frequent <i>Met</i> Oncogene Amplification in a <i>Brca1/Trp53</i> Mouse Model of Mammary Tumorigenesis

Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER&lt;sup&gt;+&lt;/sup&gt; Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Supplementary Table 2 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER&lt;sup&gt;+&lt;/sup&gt; Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes